They further showed that combining SIRPα–Fc antibodies with VEGF inhibition potentiated anti-tumor efficacy by increasing macrophage-mediated phagocytic uptake of cancer cells and inhibiting the formation of new blood vessels in tumors [239]. This evidence concerns the gene SIRPA and cancer.